However, EZH2, as a methyltransferase, demonstrates overexpression rather than mutation as the primary mechanism in MM, which exerts carcinogenesis and drug resistance, and is associated with poor prognosis [7,8,9]. Here, EZH2 is linked to Miyoshi myopathy.